{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T07:40:25Z","timestamp":1730446825401,"version":"3.28.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Korean Cancer Survivors Healthcare R&D Project through the National Cancer Center, funded by the Ministry of Health & Welfare","award":["RS-2023-CC140196"],"award-info":[{"award-number":["RS-2023-CC140196"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75230-6","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T03:02:31Z","timestamp":1730170951000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The discrepancy of somatic BRCA1\/2 pathogenic variants from two different platforms in epithelial ovarian, fallopian tube, and peritoneal cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Ji Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seog-Yun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Soo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sokbom","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Woo","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"75230_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.\u00a071, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"75230_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4143\/crt.2022.128","volume":"54","author":"MJ Kang","year":"2022","unstructured":"Kang, M. J. et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. Cancer Res. Treat.\u00a054, 330\u2013344 (2022).","journal-title":"Cancer Res. Treat."},{"key":"75230_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 108, 171\u2013182 (2002).","journal-title":"Cell"},{"key":"75230_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.molonc.2009.01.001","volume":"3","author":"AA Jazaeri","year":"2009","unstructured":"Jazaeri, A. A. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol. Oncol.\u00a03, 151\u2013156 (2009).","journal-title":"Mol. Oncol."},{"key":"75230_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12325-016-0281-1","volume":"33","author":"DM Eccles","year":"2016","unstructured":"Eccles, D. M. et al. Selecting patients with ovarian Cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review. Adv. Ther.\u00a033, 129\u2013150 (2016).","journal-title":"Adv. Ther."},{"key":"75230_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol.\u00a020, 1248\u20131259 (2002).","journal-title":"J. Clin. Oncol."},{"key":"75230_CR7","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","volume":"23","author":"I Vergote","year":"2022","unstructured":"Vergote, I. et al. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol.\u00a023, e374\u2013e84 (2022).","journal-title":"Lancet Oncol."},{"key":"75230_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.\u00a022, 1721\u20131731 (2021).","journal-title":"Lancet Oncol."},{"key":"75230_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"75230_CR10","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A. et al. Germline and somatic tumor testing in epithelial ovarian Cancer: ASCO Guideline. J. Clin. Oncol.\u00a038, 1222\u20131245 (2020).","journal-title":"J. Clin. Oncol."},{"key":"75230_CR11","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.3802\/jgo.2018.29.e56","volume":"29","author":"DH Suh","year":"2018","unstructured":"Suh, D. H. et al. Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J. Gynecol. Oncol.\u00a029, e56 (2018).","journal-title":"J. Gynecol. Oncol."},{"key":"75230_CR12","doi-asserted-by":"crossref","unstructured":"Bekos, C. et al. Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer. J. Pers. Med. 11(7) 593 (2021).","DOI":"10.3390\/jpm11070593"},{"key":"75230_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12920-022-01230-y","volume":"15","author":"PN Quy","year":"2022","unstructured":"Quy, P. N. et al. Inter-assay variability of next-generation sequencing-based gene panels. BMC Med. Genomics. 15, 86 (2022).","journal-title":"BMC Med. Genomics"},{"key":"75230_CR14","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41598-022-05589-x","volume":"12","author":"M Maekawa","year":"2022","unstructured":"Maekawa, M. et al. Precision cancer genome testing needs proficiency testing involving all stakeholders. Sci. Rep.\u00a012, 1494 (2022).","journal-title":"Sci. Rep."},{"key":"75230_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/jclinpath-2020-206840","volume":"74","author":"D Rivera","year":"2021","unstructured":"Rivera, D. et al. Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations. J. Clin. Pathol.\u00a074, 596\u2013603 (2021).","journal-title":"J. Clin. Pathol."},{"key":"75230_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jmoldx.2014.11.004","volume":"17","author":"D Trujillano","year":"2015","unstructured":"Trujillano, D. et al. Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and\/or ovarian cancer. J. Mol. Diagn.\u00a017, 162\u2013170 (2015).","journal-title":"J. Mol. Diagn."},{"key":"75230_CR17","doi-asserted-by":"publisher","first-page":"107537","DOI":"10.1016\/j.biotechadv.2020.107537","volume":"41","author":"JF Hess","year":"2020","unstructured":"Hess, J. F. et al. Library preparation for next generation sequencing: a review of automation strategies. Biotechnol. Adv.\u00a041, 107537 (2020).","journal-title":"Biotechnol. Adv."},{"key":"75230_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3343\/alm.2023.43.1.64","volume":"43","author":"Y Kim","year":"2023","unstructured":"Kim, Y. et al. Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in patients with metastatic castration-resistant prostate Cancer between Local and Central Laboratories in Korea. Ann. Lab. Med.\u00a043, 64\u201372 (2023).","journal-title":"Ann. Lab. Med."},{"key":"75230_CR19","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes, S. A. et al. COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res.\u00a043, D805\u2013D811 (2015).","journal-title":"Nucleic Acids Res."},{"key":"75230_CR20","doi-asserted-by":"crossref","unstructured":"Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017 (2017). https:\/\/doi.org\/10.1200\/PO.17.00011","DOI":"10.1200\/PO.17.00011"},{"key":"75230_CR21","doi-asserted-by":"publisher","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","volume":"44","author":"MJ Landrum","year":"2016","unstructured":"Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res.\u00a044, D862\u2013D868 (2016).","journal-title":"Nucleic Acids Res."},{"key":"75230_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"C Genomes Project","year":"2015","unstructured":"Genomes Project, C. et al. A global reference for human genetic variation. Nature. 526, 68\u201374 (2015).","journal-title":"Nature"},{"key":"75230_CR23","doi-asserted-by":"publisher","first-page":"D840","DOI":"10.1093\/nar\/gkw971","volume":"45","author":"KJ Karczewski","year":"2017","unstructured":"Karczewski, K. J. et al. The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res.\u00a045, D840\u2013D5 (2017).","journal-title":"Nucleic Acids Res."},{"key":"75230_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in Cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn.\u00a019, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"75230_CR25","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1038\/s41598-022-06885-2","volume":"12","author":"K Hatakeyama","year":"2022","unstructured":"Hatakeyama, K. et al. Tumor cell enrichment by tissue suspension enables detection of mutations with low variant allele frequency and estimation of germline mutations. Sci. Rep.\u00a012, 2953 (2022).","journal-title":"Sci. Rep."},{"key":"75230_CR26","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.22.01934","volume":"40","author":"WP Tew","year":"2022","unstructured":"Tew, W. P., Lacchetti, C. & Kohn, E. C. Panel PIitMoOCGE. Poly(ADP-Ribose) polymerase inhibitors in the management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. J. Clin. Oncol.\u00a040, 3878\u20133881 (2022).","journal-title":"J. Clin. Oncol."},{"key":"75230_CR27","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl. J. Med.\u00a0381, 2416\u20132428 (2019).","journal-title":"N Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75230-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75230-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T07:06:25Z","timestamp":1730444785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75230-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75230"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75230-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Declaration of Helsinki and approved by the Institutional Review Board of the National Cancer Center, Korea (NCC2022-0314). Due to the retrospective nature of the study, Institutional Review Board of the National Cancer Center, Korea waived the need of obtaining informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25879"}}